title: In vitro activities of faropenem against 579 strains of anaerobic bacteria.
abstract: The activity of faropenem, a new oral penem, was tested against 579 strains of anaerobic bacteria by using the NCCLS-approved reference method. Drugs tested included amoxicillin-clavulanate, cefoxitin, clindamycin, faropenem, imipenem, and metronidazole. Of the 176 strains of Bacteroides fragilis group isolates tested, two isolates had faropenem MICs of 64 micro g/ml and imipenem MICs of >32 micro g/ml. Faropenem had an MIC of 16 micro g/ml for an additional isolate of B. fragilis; this strain was sensitive to imipenem (MIC of 1 micro g/ml). Both faropenem and imipenem had MICs of < or=4 micro g/ml for all isolates of Bacteroides capillosus (10 isolates), Bacteroides splanchnicus (13 isolates), Bacteroides ureolyticus (11 isolates), Bilophila wadsworthia (11 isolates), Porphyromonas species (42 isolates), Prevotella species (78 isolates), Campylobacter species (25 isolates), Sutterella wadsworthensis (11 isolates), Fusobacterium nucleatum (19 isolates), Fusobacterium mortiferum/varium (20 isolates), and other Fusobacterium species (9 isolates). Faropenem and imipenem had MICs of 16 to 32 micro g/ml for two strains of Clostridium difficile; the MICs for all other strains of Clostridium tested (69 isolates) were < or =4 micro g/ml. Faropenem had MICs of 8 and 16 micro g/ml, respectively, for two strains of Peptostreptococcus anaerobius (MICs of imipenem were 2 micro g/ml). MICs were < or =4 micro g/ml for all other strains of gram-positive anaerobic cocci (53 isolates) and non-spore-forming gram-positive rods (28 isolates). Other results were as expected and reported in previous studies. No metronidazole resistance was seen in gram-negative anaerobes other than S. wadsworthensis (18% resistant); 63% of gram-positive non-spore-forming rods were resistant. Some degree of clindamycin resistance was seen in most of the groups tested.
authors.affiliation: Department of Medicine, Immunology and Molecular Genetics, University of California Los Angeles School of Medicine, Los Angeles, California 90024, USA. hwexler@ucla.edu
authors.forename: Hannah M
authors.initials: HM
authors.lastname: Wexler
authors.forename: Denise
authors.initials: D
authors.lastname: Molitoris
authors.forename: Shahera
authors.initials: S
authors.lastname: St  John
authors.forename: Ann
authors.initials: A
authors.lastname: Vu
authors.forename: Erik K
authors.initials: EK
authors.lastname: Read
authors.forename: Sydney M
authors.initials: SM
authors.lastname: Finegold
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001421:Bacteria, Anaerobic / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D001426:Bacterial Proteins; D004269:DNA, Bacterial / Q000235:genetics; D024881:Drug Resistance, Bacterial; D007769:Lactams; D008826:Microbial Sensitivity Tests; D020133:Reverse Transcriptase Polymerase Chain Reaction; D001618:beta-Lactamases / Q000235:genetics; D047090:beta-Lactams
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D004269:DNA, Bacterial; D007769:Lactams; D047090:beta-Lactams; D001618:beta-Lactamases; C063912:carbapenemase; C107057:fropenem